Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia. …
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech
Latest Video
New Stories
-
Outgoing President proposes dramatic expansion in funded access to anti-obesity therapies
November 27, 2024 - -
Whooping cough cases surge across Australia as vaccination rates fall
November 27, 2024 - - Latest News -
Australian-backed triple-combination hypertension treatment proceeding to regulatory submission
November 27, 2024 - - Latest News -
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 - - Australian Biotech -
Medical Cannabis company Montu appoints experienced industry executive to key policy and advocacy role
November 27, 2024 - - Latest News -
Island Pharmaceuticals says ISLA-101 shows anti-dengue activity in Phase 2a study readout
November 27, 2024 - - Australian Biotech -
Senate committee to question PBAC chair on submission deferrals
November 27, 2024 - - Latest News